Shots:
- The EC has approved Leqembi for the treatment of early Alzheimer’s disease in all 30 EEA states
- Eisai handles global development & regulatory filings for Leqembi, co-commercializing & co-promoting it with Biogen while retaining final decision-making authority. Eisai co-promotes Leqembi with Biogen in the EU (excl. Nordics) & with BioArctic in the Nordic countries, distributing it as MA Holder in all regions
- Leqembi is a humanized anti-soluble aggregated Aβ mAb that selectively binds to Aβ plaque components, reducing Aβ protofibrils & plaques in the brain
Ref: Globenewswire | Image: Eisai & Biogen & BioArctic
Related News:- Organon Acquires Regulatory and Commercial Rights of Tofidence IV Infusion (Biosimilar, Actemra) from Biogen in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
